[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 4, Number 1 (3-2014) ::
Iran J Ped Hematol Oncol 2014, 4(1): 32-38 Back to browse issues page
Assessment of Thiopurine–based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia
Mrs F Azimi, Mrs M Jafariyan, Mrs S Khatami, Mr Y Mortazavi , Dr M Azad
Abstract:   (1874 Views)
For the past half century, thiopurines have earned themselves a reputation as effective anti-cancer and immunosuppressive drugs. Thiopurine S-methyltransferase (TPMT) is involved in the metabolism of all thiopurines and is one of the main enzymes that inactivates mercaptopurine. 6-MP is now used as a combination therapies for maintenance therapy of children with acute lymphocytic leukemia (ALL). In all patients receiving mercaptopurine, there is a risk of bone marrow suppression. TPMT activity is inherited as a monogenic, co-dominant trait. More than 25 variants are known. Genetic testing is available for several TPMT variant alleles. Most commonly TPMT*2, *3A, and *3C are tested for, which account for >90% of inactivating alleles. Differences in DNA that alter the expression or function of proteins that are targeted by drugs can contribute significantly to variation in the responses of individuals.Genotyping may become part of routine investigations to help clinicians tailor drug treatment effectively. This success is mainly due to the development of combination therapies and stratification of patients according to risk of treatment failure and relapse, rather than the discovery of new drugs. The aim of this study was to investigate the effect of genotype or methyltransferase enzyme activity before starting therapy in children with ALL. This can prevent the side effect of thiopurine drugs. In fact, the common polymorphism of this enzyme in population could be a prognostic factor in relation to drug use and treatment of patients with ALL.
Keywords: Acute lymphoblastic leukemia, 6-Mercaptopurine, 6-Thioguanine, Azathioprine, Myelosuppression, polymorphism
Full-Text [PDF 143 kb]   (543 Downloads)    
Type of Study: Research | Subject: Special
Received: 2014/03/15 | Accepted: 2014/03/15 | Published: 2014/03/15
Add your comments about this article
Your username or email:

Write the security code in the box >



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Azimi F, Jafariyan M, Khatami S, Mortazavi Y, Azad M. Assessment of Thiopurine–based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia. Iran J Ped Hematol Oncol. 2014; 4 (1) :32-38
URL: http://ijpho.ssu.ac.ir/article-1-156-en.html
Volume 4, Number 1 (3-2014) Back to browse issues page
Iranian Journal of Pediatric Hematology and Oncology
Persian site map - English site map - Created in 0.328 seconds with 831 queries by yektaweb 3465